search for books and compare prices
Tables of Contents for Ovarian Cancer
Chapter/Section Title
Page #
Page Count
List of contributors
xiii
Abbreviations
xxi
Part 1 Aetiology
Epidemiology of sporadic ovarian cancer
Daniel W. Cramer
3
6
Associations between infertility, its treatment, and ovarian cancer risk
Ingemar Persson
9
6
The molecular basis of sporadic ovarian cancer
Angeles Alvarez and Andrew Berchuck
15
14
Overview of the aetiology of familial ovarian cancer
Ronald P. Zweemer
29
8
The prevalence of mutations in BRCA1 and BRCA2
Michael R. Stratton
37
4
The penetrance of BRCA1/2 mutations
Jeffery P. Struewing
41
4
Founder mutations of BRCA1/2
Uziel Beller Baruch Modan Ofer Lavie Bella Kaufman Galit Hirsh-Yechzkel Orit Gotfeld Angela Chetrit Raphael Catane and Ephrat Levy-Lahad
45
4
Clinical implications of genetic testing
Andrew Berchuck P. Andrew Futreal and Joellen S. Schildkraut
49
8
Part 2 Natural history and Pathology
Pathology of epithelial ovarian cancer
Harold Fox and Naveena Singh
57
10
Pathology of borderline ovarian malignancy
Harold Fox
67
8
Primary non-epithelial ovarian cancers
Naveena Singh and David Lowe
75
10
Metastases in the ovary
Naveena Singh and David Lowe
85
6
Genetic analysis of putative precursors of ovarian cancer
Ian G. Campbell Sarah J. Morland Koshiro Obata Phillippa J. Neville and Nicola Thomas
91
6
Molecular pathogenesis of borderline and invasive ovarian tumours
Samuel C. Mok Karen H. Lu Shu-wing Ng Gary K. Tiu William R. Welch Debra A. Bell and Ross S. Berkowitz
97
10
Part 3 Tumour biology
The application of novel technology to the study of ovarian cancer
Monica R. Brown Michael Emmert-Buck David B. Krizman Emmanuel Petricoin Lance A. Liotta and Elise C. Kohn
107
6
The biology of the ovarian surface epithelium
Rudi Bao Abbas Abdollahi and Thomas C. Hamilton
113
6
The tumour microenvironment of epithelial ovarian cancer
Frances Burke Chris Scotton Kate Scott Robert Moore Caroline Arnott and Fran Balkwill
119
6
ARH1 (NOEY2), a novel imprinted tumor suppressor gene in ovarian cancer
Yinhua Yu Fengji Xu Hongqi Peng Xianjun Fang Shulei Zhao Weiya Xia Wen-lin Kuo Joe W. Gray Michael Siciliano David Hogg Andrew Berchuck Kelly Hunt Gordon B. Mills and Robert C. Bast, Jr
125
6
Regulation of angiogenesis in ovarian cancer: role of p53, vascular endothelial growth factor, and hypoxia
E. Ferreux C.E. Lewis C.W. Perrett and M. Wells
131
6
Role of Fas/FasL in the control of human ovary cancer growth and progression
Delia Mezzanzanica Alessandra Mazzoni Donatella R.M. Negri Mariangela Figini Maria I. Colnaghi and Silvana Canevari
137
8
Part 4 Prevention and screening
The surgical prevention of ovarian cancer
David H. Oram
145
8
Chemoprevention of ovarian cancer
Christine E. Szarka Thomas C. Hamilton Andres J.P. Klein-Szanto and Robert F. Ozols
153
8
Biologic effect of progestins on ovarian epitheium: cancer prevention through apoptosis?
Gustavo C. Rodriguez David Walmer Mark Cline Hannah Krigman Regina Whitaker Pamela D. Isner Bruce Lessey Connette McMahon Jeffrey Marks James Petitte Donna Carver Kenneth Anderson Andrew Berchuck John Barnes and Claude Hughes
161
10
The current status of screening for ovarian cancer
Usha Menon and Ian J. Jacobs
171
8
Optimizing the use of ultrasonography in ovarian cancer screening
Paul DePriest
179
4
Doppler ultrasound derived indices in screening and diagnosis of ovarian cancer
Kenneth J.W. Taylor and Andrea Lundell
183
6
Differentiating the risk of ovarian cancer calculation from CA125 velocity: a new concept for optimizing CA 125 screening for ovarian cancer
Steven J. Skates
189
10
Socio-economics of ovarian cancer screening
Nicole Urban Martin McIntosh Lauren Clarke Ian Jacobs Beth Karlan Garnet Anderson and Charles Drescher
199
10
The management of familial ovarian cancer
Paul D. Pharoah and James Mackay
209
12
Part 5 Diagnostic and prognostic techniques
Clinical diagnosis including paraneoplastic syndromes
Chris N. Hudson Thomas J. Ind and O. Marigold Curling
221
12
Serum tumour markers in the clinical management of ovarian cancer
Robert P. Woolas
233
10
Three-dimensional ultrasound and color-flow studies
A. Kurjak and S. Kupesic
243
14
CT and MRI of ovarian cancer
S.A.A. Sohaib and R.H. Reznek
257
12
Radionuclide imaging
Keith E. Britton Faria Nasreen Hikmat Jan and Marie Granowska
269
6
Telomerase in ovarian cancer: a possible diagnostic tool and therapeutic target?
G. Bea A. Wisman Marco N. Helder Steven de Jong Elisabeth G.E. de Vries and Ate G.J. van der Zee
275
6
Detection of circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian cancer
Christian Marth Hanne Høifødt Lise Walberg Janne Kæarn Ole Mathiesen Marianne Andresen Claes Trope and Øystein Fodstad
281
8
Part 6 Surgical treatment and organization of care
Overview of primary surgery for ovarian cancer
Thomas E.J. Ind and John H. Shepherd
289
10
Interval debulking surgery significantly increases the survival and progression-free survival in advanced epithelial ovarian cancer patients: an EORTC Gynaecological Cancer Co-operative Group study
Maria E.G. van der Burg Mat van Lent Anna Kobierska M.R. Pittelli Guiceppe Favalli Angel J. Lacave M. Nardi Guido Hoctin Boes Ivana Teodorovic and Sergio Pecorelli
299
6
The role of surgery in relapse and palliation of ovarian cancer
Sean Kehoe and Christopher Mann
305
6
The role of minimal access surgery in ovarian cancer
Robin A.F. Crawford
311
8
The organization of care
H.C. Kitchener
319
4
Patterns of care in ovarian cancer
Edward L. Trimble
323
10
Part 7 Adjuvant and palliative therapy for ovarian cancer
Current chemotherapy options in ovarian cancer
Martin Gore Francisco Sapunar and David Gibbs
333
8
Chemotherapy for epithelial cancer of the ovary
Jonathan Shamash and Maurice Slevin
341
10
Neoadjuvant chemotherapy in advanced ovarian carcinoma: present and future prospects
Ignace Vergote
351
4
Randomized trials in epithelial ovarian cancer: the Gynecologic Oncology Group studies
Jonathan S. Berek and Robert F. Ozols
355
8
Part 8 Novel therapies: the future
Angiogenesis in epithelial ovarian cancer: an important biologic event and therapeutic target
Elise C. Kohn
363
8
Delivery of genes to ovarian cancer using targeted vectors based on self-assembling polymers
Kerry D. Fisher Christopher M. Ward Nigel Acheson and Leonard W. Seymour
371
6
Corporate drug discovery strategies
Mark P. Smith and George R. P. Blackledge
377
2
DNA mismatch repair and drug resistance
Stephen B. Howell Xinjian Lin and Heung-Ki Kim
379
6
Gene therapy and immunomodulation
Rosalind Graham Michael Smith Lukas Heukamp Izsabel Correa Tim Plunkett Moira Shearer David Miles Joy Burchell and Joyce Taylor-Papadimitriou
385
6
Preclinical and phase I clinical studies of combinations of chemotherapy with recombinant adenovirus containing full-length, human p53 tumor suppressor gene cDNA for p53-mutant ovarian cancer
M.D. Pegram G. Konecny R. Buller I. Runnebaum D.J. Slamon L.L. Nielsen J. Horowitz and B.Y. Karlan
391
8
Paclitaxel resistance in human ovarian cancer: role of apoptosis-related proteins
Stephen R.D. Johnston Mansour S. Al-Moundhri Lloyd R. Kelland and Martin E. Gore
399
8
Trials of p53 gene therapy: rationale and Preliminary studies
R.E. Bulter M. Pegram I. Runnebaum JoAnn Horowitz T.E. Buekers Thomas P. Salko M.E. Rybak M.S. Shahin R. Kreienberg B. Karlan and D. Slamon
407
6
Phosphatidylinositol 3'-kinase as a target in ovarian cancer: from genomics to therapeutics
Yiling Lu Laleh Shayestri Ruth Lapushin Singxing Yu Bruce Cuevas Xianjun Fang Astrid Eder Tatsuro Furui Daniel Plikoff Wen-Lin Kuo Russ Baldocchi Bart Vanhaesebroeck Robert C. Bast Dan Pinkel Kathy Siminovitch Robert Jaffe Joe Gray and Gordon B. Mills
413
10
Index
423
<